To include your compound in the COVID-19 Resource Center, submit it here.

Amgen, Daiichi Sankyo deal

Amgen granted Daiichi exclusive rights to commercialize nine biosimilars in Japan. Amgen will be responsible for development

Read the full 172 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE